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Abstract
Background: Hereditary Spastic Paraplegia (HSP) represents a large group of clinically and genetically
heterogeneous disorders linked to over 70 different loci and more than 60 recognized disease-causing genes.
A heightened vulnerability to disruption of various cellular processes inherent to the unique function and
morphology of corticospinal neurons may account, at least in part, for the genetic heterogeneity.
Methods: Whole exome sequencing was utilized to identify candidate genetic variants in a four-generation
Siberian kindred that includes nine individuals showing clinical features of HSP. Segregation of candidate variants
within the family yielded a disease-associated mutation. Functional as well as in-silico structural analyses confirmed
the selected candidate variant to be causative.
Results: Nine known patients had young-adult onset of bilateral slowly progressive lower-limb spasticity, weakness
and hyperreflexia progressing over two-to-three decades to wheel-chair dependency. In the advanced stage of
the disease, some patients also had distal wasting of lower leg muscles, pes cavus, mildly decreased vibratory
sense in the ankles, and urinary urgency along with electrophysiological evidence of a mild distal motor/sensory
axonopathy. Molecular analyses uncovered a missense c.2155C > T, p.R719W mutation in the highly conserved
GTP-effector domain of dynamin 2. The mutant DNM2 co-segregated with HSP and affected endocytosis when
expressed in HeLa cells. In-silico modeling indicated that this HSP-associated dynamin 2 mutation is located in a
highly conserved bundle-signaling element of the protein while dynamin 2 mutations associated with other
disorders are located in the stalk and PH domains; p.R719W potentially disrupts dynamin 2 assembly.
Conclusion: This is the first report linking a mutation in dynamin 2 to a HSP phenotype. Dynamin 2 mutations
have previously been associated with other phenotypes including two forms of Charcot-Marie-Tooth neuropathy
and centronuclear myopathy. These strikingly different pathogenic effects may depend on structural relationships
the mutations disrupt. Awareness of this distinct association between HSP and c.2155C > T, p.R719W mutation will
facilitate ascertainment of additional DNM2 HSP families and will direct future research toward better understanding
of cell biological processes involved in these partly overlapping clinical syndromes.
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Background
Hereditary spastic paraplegia (HSP) comprises a group
of clinically and genetically heterogeneous diseases that
affect the upper motor neurons and their long axonal
projections. The hallmark of hereditary spastic paraple-
gia (HSP) is progressive degeneration of the corticosp-
inal tracts, often in a length-dependent manner, and
progressive spasticity as the major clinical feature;
neuropathological studies have identified axon degener-
ation of the corticospinal tracts and fasciculus gracilis fi-
bers [1]. The key diagnostic findings are lower limb
weakness, increased muscle tone, hyperreflexia, extensor
plantar responses, and gait spasticity [2].
The burden inherent to corticospinal neurons with their
long axonal processes spanning from motor cortex to dis-
tant segments of the spinal cord is likely to involve various
cellular vulnerabilities that could account for the broad
genetic heterogeneity of HSPs. Variant forms of HSP arise
from mutations in genes directly implicated in membrane
traffic, mitochondrial function, endoplasmic reticulum
shaping/distribution, myelination, lipid/cholesterol metab-
olism, bone morphogenetic protein signaling, and endoly-
sosomal function, as well as endosome and microtubule
dynamics [3, 4]. Typically, the longest fibers — those con-
necting to the lower spinal cord segments — are the earli-
est to experience changes in their terminal regions that
predate changes in cell bodies, leading to suggestions that
impact on axonal traffic is a common mechanism of HSP.
In this regard, HSP may be viewed as a central nervous
system counterpart of the axonal form of Charcot-Marie-
Tooth (CMT2) neuropathy, a clinically and genetically
heterogeneous group of disorders of the peripheral ner-
vous system marked by length-dependent distal axon de-
generation of motor and sensory nerves [5].
We report on a novel association of an autosomal
dominant HSP phenotype with a heterozygous DNM2
mutation. Dynamins are highly conserved large GTPases
that play a critical role in clathrin-mediated endocytosis.
They participate in converting the nascent invaginated
clathrin-coated pit into a fully formed vesicle and in
detaching the vesicle from the plasma membrane (mem-
brane fission) [6]. In developing neurons, both endocyto-
sis and exocytosis are critical for delivery of nutrients
and building materials. Clathrin-mediated endocytosis
plays a particularly important and specialized role at
neuronal synapses [7]. Dynamin isoforms dynamin 1 and
dynamin 3 are expressed in neurons, while dynamin 2 is
found ubiquitously, including the CNS [8]. Dynamin 2 is
involved in several other cellular processes, such as
regulation of neuronal morphology, axonal growth and
formation of growth cones, centrosome cohesion, actin-
and microtubular dynamics [9].
Dynamin 2 is a 100 kDa multidomain protein com-
posed of a highly conserved catalytic N-terminal GTPase
domain (GTPase), a middle domain (MD) driving dyna-
min oligomerization, a pleckstrin homology domain (PH)
critical for the interaction with membrane phosphoinosi-
tides, a GTPase effector domain (GED) that activates
GTPase upon assembly of dynamin oligomers into higher
order structures, and a less conserved C-terminal proline/
arginine rich domain (PRD) which directs dynamin to
endocytic sites and is a major site for interacting with
other proteins [10, 11] (Fig. 1).
Distinct mutations in dynamin 2 have previously been
associated with other phenotypes including two forms of
Charcot-Marie-Tooth disease: axonal CMT2M (MIM#
606482) originally reported by Züchner et al. [12] and
intermediate form CMTDIB (MIM# 606482) reported
by Kennerson et al. [13]; centronuclear myopathy
ADCNM (MIM# 160150) originally reported by Bitoun
et al. [14], and lethal congenital contractures syndrome
type 5 LCCS5 (MIM#615368). The majority of CMT-
associated DNM2 mutations is located in the N-terminal
part of the pleckstrin homology domain (Fig. 1), while a
distinct set of mutations, mainly those found in the
middle, PH, and PH/GTPase-effector boundary, is linked
to autosomal-dominant centronuclear myopathy. The
mechanisms by which various DNM2 mutations affect
discrete tissues and lead to distinct phenotypes remain
unknown.
Methods
Family pedigree and patient evaluation
Chronic neurological disorders are highly prevalent in
the Sakha (Yakut) Republic, Russian Federation. In the
process of systematic ascertainment of patients with
Viliuisk encephalomyelitis and related disorders [15], a
multigenerational HSP family was identified. This 4-
generational Siberian family included 9 patients. The
oldest family member (I:2, Fig. 2) known to be affected
by history had stiff gait and progressive muscle weakness
of the lower extremities for at least 10 years before his
death at 63. His 3 sons from two marriages (II:1, II:4,
and II:6) developed the “family disease”. They were re-
peatedly examined over the following three decades and
diagnosed with hereditary spastic paraplegia. In the third
generation, three sons of patient II:4, also from separate
marriages, and a daughter of patient II:6 developed the
same disease (III:2, III:3, III:5, and III:7). Finally, a great-
grandson (IV:1) was the youngest patient to be diag-
nosed. Pedigree was constructed based on cross inter-
views of patients and closest family members.
The study was approved by the Institutional Review
Boards of the Institute of Health, North-Eastern Federal
University, Yakutsk, and the Yakutsk Research Center,
Siberian Branch of the Russian Academy of Medical
Sciences. The statement confirmed in writing that the
Clinical protocol complied with the Declaration of
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Helsinki. A written informed consent was obtained from
each participant.
After obtaining informed consent, 5 affected and 5 un-
affected family members underwent a neurological exam
that included assessment of mental status, cranial
nerves, muscle strength (MRC scale), coordination, ten-
don reflexes, muscle bulk, muscle tone, plantar re-
sponses, foot deformity, and gait. Evaluation of sensory
impairment included clinical testing for pain and
temperature sensation, vibration and position sense.
Electrophysiological investigation performed in 3 pa-
tients (III:3, III:5, and IV:1) included motor and sensory
nerve conduction velocities (NCV), compound muscle
action potential (CMAP) amplitudes, distal motor
latencies (DML), sensory NCV and sensory nerve action
potential (SNAP) amplitudes recorded under standard
conditions from the median, ulnar, peroneal, tibial, and
sural nerves. Routine clinical MRI of the spinal cord was
also obtained in three cases. Blood for DNA extraction
was drawn from 9 family members.
Exome sequencing
WES was performed using genomic DNA extracted
from peripheral white blood cells of patients II:6 and
III:3. Exome capture utilized TruSeq Kit v1 (Illumina,
Sand Diego, California) in accordance with manufac-
turer’s instructions. Library construction, sequence gen-
eration, sequence alignment to the reference genome
Fig. 2 Pedigree of the Siberian family with Hereditary spastic paraplegia. Filled symbols indicate individuals affected with HSP; open symbols
represent unaffected family members. The p.R719W mutation was identified in the affected family members II:6, III:2, III:3, III:7, IV:1, but the test for
the mutation was negative in unaffected individuals III:1, IV:2, IV:3, IV:4
Fig. 1 Domain structure of dynamin 2 and location of known disease-causing mutations. Mutations associated with Central nuclear myopathy are
shown in black in the upper set; mutations associated with subtypes of Charcot-Marie-Tooth neuropathy are shown in blue at the bottom of the
diagram. A homozygous mutation associated with Lethal Congenital Contracture Syndrome appears in green in the upper set. The p.R719W
mutation identified in the Siberian family with Hereditary Spastic Paraplegia is shown in red within the bottom set
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(UCSC GRCh37/hg19), variant calling, and identification
of potentially pathogenic variants were performed as de-
scribed [16]. Variant analysis was performed using an
autosomal dominant genetic model. Only variants satis-
fying stringent coverage and genotype quality criteria
were included in further downstream variant analysis.
WES generated variants were further validated by segre-
gation analysis to 3 additional affected and 4 unaffected
members of the Siberian family using standard Sanger
sequencing of amplified DNA fragments.
Endocytosis assay
The wild-type human DNM2 in pmCherry-N1 vector
(Addgene plasmid 27689) was a kind gift from Dr. C.
Merrifield [17]. The c.2155C > T, p.R719W mutation was
introduced into the pmCherry-N1 DNM2 plasmid using
the Quick-Change Site Directed Mutagenesis kit accord-
ing to manufacturer’s protocol (Agilent Technologies,
Santa Clara, CA). The integrity of all plasmids was con-
firmed by DNA sequencing.
HeLa cells were grown in Dulbecco's modified Eagle’s
medium (Life Technologies, Grand Island, NY) supple-
mented with 10 % fetal bovine serum. 50-60 % confluent
cells were transfected with plasmids containing wild type
or mutant DNM2 by using transfection reagent HilyMax
(Dojindo Molecular Technologies, Rockville, MD) ac-
cording to the manufacturer’s protocol. Cultures were
then incubated in growth medium. At 20 hrs post-
transfection, the cells were serum starved for 1 h and
treated with 25ug/ml Alexa-Flour 488 conjugated Trans-
ferrin (Life Technologies, Frederick, MD) for 15 min at
37 °C. Cells labeled with fluorescent transferrin were
then washed and fixed with 4 % paraformaldehyde.
Immunofluorescene analysis was performed as previ-
ously described [18]. Cells were visualized with a Zeiss
LSM 510 confocal microscope. Transferrin immuno-
fluorescent signal was measured by utilizing ImageJ
(Image Processing and Analysis in Java, National Insti-
tutes of Health) software. Mean fluorescence was first
measured in the background; the corrected total trans-
ferrin fluorescence signal was then compared between
cells expressing WT and mutant DNM2 constructs.
Statistical significance was evaluated using the Student’s
t-test. P-value <0.05 was considered significant.
Structural studies
Molecular models of dynamin 2 wild type and p.R719W
were generated by I-TASSER [19–21], using dynamin 1
as a template [22]. The sequence homology between
dynamin 1 and 2 is 78 % identical overall and 87 % in
the GTPase domain. The position of R719 in dynamin 1
is R725. The molecular models were visualized and H-
bonds calculated by Chimera [23]. The dynamin 1
tetramer image was generated from docked crystal struc-
tures in the 3D density map of K44A-dynamin 1 [24].
Results
Phenotypic features and disease outcomes
The pattern of disease inheritance in this family was
autosomal dominant (Fig. 2). Clinical information ob-
tained at evaluation of 5 affected family members (II:6,
III:3, III:5, III:7, and IV:1) is summarized in Table 1. The
illness had an insidious onset between the ages of 10
and 37 years (mean, 26 years) with impaired gait, muscle
stiffness and weakness in the lower limbs. Further pro-
gression of illness in patients II:6 and III:5 led to severe
bilateral lower limb muscle weakness requiring the use
of cane and eventual wheel-chair dependency by the
28th and 23rd years of illness. Three patients (I:2, II:1,
and III:2) died after an illness lasting for 23 to 32 years,
and one (II:4) died in an accident.
At examination (Table 1), a single patient had mild de-
velopmental cognitive delay. No optic nerve atrophy,
nystagmus, or signs of ataxia were found. Cranial nerves
were intact, bulbar functions preserved until late in the
illness, none showed dysphagia, and only a single patient
(III:5) had moderate spastic dysarthria. Upper extrem-
ities muscle bulk, strength, muscle tone, reflexes, sensa-
tion and coordination were not affected. In the lower
limbs, typical features of upper motor neuron involve-
ment were present in all patients, including spasticity,
reduced muscle strength, tightness of Achilles heels.
Deep tendon reflexes were increased in all patients with
clonus in 3 and bilateral Babinski sign in 4. Moderate
muscle atrophy of lower leg muscles was noticed in ad-
vanced illness in patients II:6, III:3, III:5, and one patient
had flexion contracture of leg muscles and chronic de-
cubitus ulceration (II:6). All patients had profoundly
spastic gait. Sphincter control abnormalities manifesting
as urinary urgency were observed late in the illness in
two patients (II:6 and III:5). Clinical testing for pain,
temperature, and position sense did not reveal any defi-
cits. Mild distal vibratory sense impairment was detected
in patients II:6 (inconsistently), III:3, and III:5 late in the
course of illness. Scoliosis was present in one patient
and bilateral pes cavus in all examined patients. MRI of
the spinal cord performed in patients III:3, III:5, and
IV:1 showed no evidence for cord compression, cord at-
rophy or intrinsic spinal cord abnormalities. There was
no evidence of multisystem involvement as determined
by routine blood count and routine blood chemistry. In
summary, the clinical course in five affected individuals
over a multi-decade observation period was overwhelm-
ingly consistent with upper motor neuron dysfunction
leading to progressive spasticity. Only late in the course
of illness symptoms suggestive of a mild peripheral in-
volvement in the form of mild sensory changes and
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distal muscle atrophy became apparent. No chronic
neurological diseases were found among other members
of the extended family or other inhabitants of this village.
Electrodiagnostic studies
Motor and sensory nerve conduction studies were per-
formed in patients III:3, III:5, and IV:1 (Table 2). Patients
III:3 and III:5 were in advanced phases of illness at the
17th and 32nd year from disease onset, patient IV:1 was
the youngest in this family at the age of 17 years, in the
7th year after the disease onset. In the n.medianus, con-
duction studies revealed mostly preserved distal motor la-
tency (DML), motor nerve conduction velocities (NCV)
and compound muscle action potentials (CMAP). In the
lower limbs, stimulation of n.peroneus profundus and
n.tibialis posterior showed reduced NCV and CMAP, most
significantly in patients with advanced disease. Sensory
nerve action potential (SNAP) amplitudes in n.suralis
were also severely affected in patients with advanced
disease. The electrodiagnostic study revealed an axonal
impairment in motor and sensory peripheral nerves con-
fined to the distal lower extremities .
Genetic analysis
Prior to exome sequencing, coding regions of common
dominant HSP genes had been analyzed by Sanger se-
quencing, including SPAST (spastin) linked to autosomal
dominant SPG4 (MIM# 18601) and ATL1 (atlastin)
causing SPG3A (MIM# 182600), genes that account for
37-46 % and 6-11 % of dominant HSP cases [25]. No
pathogenic changes were identified.
Exome sequencing was performed in two affected indi-
viduals, II:6 and III:3 (Fig. 2). A number of filtering steps
were used to prioritize sequence variants (Table 3), be-
ginning with the requirement that the variant had to be
shared by two studied affected members of the Siberian
Table 1 Clinical manifestations of Hereditary spastic paraplegia in members of the Siberian family
Patient II:6 III:3 III:5 III:7 IV:1
Age at Onset, yrs 29 26 27 37 10
Age at Exam, yrs 62 43 59 39 17
Presenting feature Weakness spasticity Weakness spasticity Muscle weakness Muscle weakness Muscle weakness
Cognitive function normal forgetful Cognitive delay (mild) normal normal
Bulbar dysfunctions no no dysarthria no no
Leg Spasticity ++++ ++++ ++++ ++ +++
Muscle contracture - - +++ - -
Muscle weakness (MRC scale):
Knee flexion 3.5 2.5 2 2 4
Knee extention 3.5 3 2 2 4.5
Ankle flexion 4 3 1.5 2.5 5
Ankle extention 3.5 3.5 1.5 2 5
Toes 3 3 1 1.5 3
Muscle wasting ++ ++ ++ - -
Hyperactive reflexes:
Knee +++ ++ ++ ++ ++
Ankle ++ +++ +++ ++ +++
Clonus - + + + +
Babinski sign bilateral no bilateral bilateral bilateral
Decreased abdominal reflexes no no ++ no no
Spastic gait ++++ ++++ ++++ ++ +++
Pinprick - - - - -
Vibration +? + + - -
Bladder Control Urinary urgency normal Urinary urgency normal normal
Pes cavus + + +++ + ++
Ulcerations on legs ++ no no no no
Outcome Bedridden Ambulatory Wheelchair Ambulatory Ambulatory
Footnote: "-" or "no" not observed, "+" sign expressed weakly, "++" and "+++" expressed moderately, "++++" expressed strongly, "+?" expressed intermittently,
numbers - muscle strength assessment according to the Medical Research Council (MRC) grading scale
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family in heterozygous state, assuming a dominant
model. Variants in non-coding regions and synonymous
SNPs were excluded. Candidates were further restricted
by excluding variants reported to have occurred in adult
cohort of over 900 subjects participating in the ClinSeq
project (ClinSeq www.genome.gov/20519355) or the 1000
genome project. Variant population frequency was add-
itionally examined using the ExAC data set. Missense
variants were further prioritized by the degree of func-
tional disruption predicted by PolyPhen-II (www.gene-
tics.bwh.harvard.edu/pph2/), SIFT [26], MutationTaster
(www.mutationtaster.org/), and CADD (Combined An-
notation–Dependent Depletion) - a single-annotation
method used to prioritize functional, deleterious and
pathogenic variants across many functional categories,
effect sizes, and genetic architectures [27]. Exome se-
quencing did not identify any predicted or known patho-
genic changes in previously identified HSP-associated
genes. Selected variants were then assessed based on
encoded protein expression and function. Considering
that our patients had an adult onset neurodegenerative
disorder with high penetrance, we excluded genes with
Table 2 Results of nerve conduction studies in patients with Hereditary spastic paraplegia caused by a c.2155C > T, p.R719W
mutation in DNM2
Patients III:3 III:5 IV:1 Normal values
Symptom duration (years) at time of study 17 32 7
Motor nerve conduction studies
n.Medianus
Distal motor latency (m/s) 3.6 ND 3.5 <4.2
Compound muscle action potential (mV)a 4.5 ND 8.7 >5.0
Motor nerve conduction velocity (m/s) 48.2 ND 57.1 >47.6
n.Peroneus
Distal motor latency (m/s) 4.49 NR 5.1 <6.5
Compound muscle action potential (mV)a NR 0.04 0.21 >3.0
Motor nerve conduction velocity (m/s) NR NR 40.6 >40.5
n.Tibialis posterior
Distal motor latency (m/s) NR NR 6.2 <6.0
Compound muscle action potential (mV)a NR 0.5 1.9 >5.0
Motor nerve conduction velocity (m/s) NR NR 39.7 >40.0
Sensory nerve conduction studies
n.Medianus
Distal sensory nerve conduction velocity (m/s)b 61.4 ND 64.5 >47.2
Sensory nerve action potential amplitude (μV) 10 ND 16.6 >5.0
n.Suralis
Distal sensory nerve conduction velocity (m/s) NR 38.5 42.8 >33.2
Sensory nerve action potential amplitude (μV) 0.7 0.43 5.82 >6.0
ND not done
Bold: outside normal range
aDistal motor response amplitude
bOrthodromic stimulation
NR no response
Table 3 Number of genetic variants selected from the overall
number of candidates based on each step of the adopted
filtering strategy
Filtering steps Number of variants
HET variants shared by patients II:6 and III:3 51,141
Coding variants 3,664




not benign and/or SIFT not tolerated
28
CADD > =10 13
Selected based on excess HET alleles
in ExAC dataset
8
Variants in genes moderately or strongly
expressed in the CNS
7
Variants in genes functionally involved
in other CNS functions than embryonic
development or tumor suppression
4
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no expression in the CNS or genes involved in early em-
bryonic development. Based on analysis of whole exome
sequencing data, 4 heterozygous variants were identified
under autosomal dominant model. Table 4 provides in-
formation regarding the encoded proteins function, ex-
pression, and the known disease associations. These four
strongest candidates were tested for segregation within
the Siberian family (Table 5). The results of this analysis
indicated that DNM2 p.R719W variant is the only one
that segregated perfectly.
DNM2 variant
The identified DNM2 missense substitution is located at
NM_001005360:c.2155C > T; Chr19(GRCh37):g.109398
08C > T in exon 19 of the DNM2 gene, which replaces
Arginine (R) with Tryptophan (W) (p.R719W) in the
encoded dynamin 2 (Fig. 3a). The region is highly con-
served at the amino acid level, up to the worm (Fig. 3b).
The p.R719W mutation is in the GTPase effector (GED)
domain (Fig. 1). The variant is predicted to be damaging
or deleterious by all methods employed in the study.
The variant was seen only once in an individual of
South Asian descent in the entire Exome Aggregation
Consortium data set that comprises exomes of 60,706
unrelated individuals sequenced as part of various
disease-specific and population genetic studies
(www.exac.broadinstitute.org).
Validation by Sanger sequencing and further segrega-
tion to other family members shows that only the af-
fected members II:6, III:2, III:3, III:7, and IV:1 are
heterozygous for the c.2155C > T, p.R719W change
whereas unaffected individuals III:1, IV:2, IV:3, and IV:4
are homozygous reference (Table 5). We conclude that
the DNM2 c.2155C > T, p.R719W variant is the under-
lying molecular basis for the HSP phenotype in the
Siberian family.
Functional study
To investigate the effects of the disease-related dynamin
2 p.R719W mutant, we evaluated clathrin-mediated
endocytosis in HeLa cells transiently transfected with
the wild type and mutant dynamin 2 following incuba-
tion with fluorescently labeled transferrin. We observed
a prominent punctate staining in cells transfected with
p.R719W DNM2 (Fig. 4), a phenomenon morphologic-
ally similar to that reported for other DNM2 mutations
causing CMT and CNM [28]. There was a significant de-
crease in transferrin uptake in cells expressing mutant
dynamin 2. This decrease was evident in all transfected
cells and was especially significant (more than 50 %) in
cells marked by arrows. The granules are localized most
prominently in the perinuclear area, likely in the endoso-
mal compartment. The results suggest that inhibited
endocytosis is part of the pathophysiological mecha-
nisms leading to HSP in this family.
Structural models
The HSP mutation p.R719W is located in the three-helix
bundle of dynamin called the bundle-signaling element
(BSE) (Fig. 5a). It is intriguing that p.R719W is the only
disease-associated mutation found in this region. Both
CMT and CNM mutations are located in the stalk (Mid-
dle/GED) and PH domains of the protein (Fig. 5a). The
BSE undergoes a large conformational change upon
GTP hydrolysis that has been described as the power
stroke of dynamin [29, 30]. A mutation in this region
suggests a defect in propagating the BSE conformational
change to the rest of the molecule and assembled helical
polymer. In addition, the mutation is located near a
hinge between the BSE and the stalk and as indicated by
fewer H-bonds (1 H-bond in W719 compared to 3 H-
bonds in R719), p.R719W may disrupt the connection
between these domains (Fig. 5b). The potential disrup-
tion of R719W in the assembled protein is further






Pathogenic prediction/score Encoded protein
expression
Encoded protein function and known
disease associationsPphen/SIFT CADD Grant-
ham




24.2 23 Brain Involved in synaptic function and
neuronal cell signaling
DSCAML1 Down syndrome cell
adhesion molecule like 1
p.I1742N Damaging/
deleterious
31 149 Brain, heart, liver,
pancreas, skeletal muscle
Involved in neuronal and axonal
migration, cell adhesion, neuronal
self-avoidance




17.13 21 Brain, testis, trachea Involved in axonal transport – moving
vesicles, organelles, and signaling
molecules along the axon
DNM2 Dynamin 2 p.R719W Damaging/
deleterious
14.7 101 Ubiquitously expressed Clathrin mediated endocytosis and
intracellular membrane trafficking.
Linked to Centronuclear myopathy
and Charcot-Marie-Tooth neuropathy
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illustrated by examining the dynamin tetramer (Fig. 5c,
asterisks).
Discussion
The Siberian family under study had a history compat-
ible with autosomal dominant transmission of a young-
adult onset slowly progressive bilateral leg spasticity cor-
responding to typical clinical manifestations of HSP:
each studied patient had lower extremity hyperreflexia,
muscle weakness, and spastic gait. Some patients also
showed wasting of lower leg muscles, pes cavus, de-
creased vibratory sense in the ankles, and urinary ur-
gency as late features of illness. There was no optic
neuropathy, retinopathy, extrapyramidal symptoms, de-
mentia, ataxia, ichthyosis, or deafness described as part
of the “complicated” subtypes of HSP. Alternative diag-
noses were excluded based on the results of clinical
studies and routine laboratory investigations. Nerve con-
duction studies in patients with advanced disease
revealed motor and sensory axonal neuropathy in distal
lower extremities, a feature reported in other subtypes
of HSP [31].
Exome sequencing methodology was used for genetic
analysis of this HSP family. There are well known limita-
tions to exome sequencing as a method of detection of
the causative mutation. Structural genomic alterations,
changes in regions not captured by this technology such
as translocations, changes in regulatory regions or in-
trons, may be responsible for the clinical phenotypes.
But subsequent analysis of tissue expression, structural
and functional characteristics of the candidate genetic
variants, and segregation within the pedigree as applied
in this study are helpful in the process of detection of
the disease-associated variant.
The identification of the DNM2 p.R719W mutation as
the cause of HSP in this family brought attention to the
fact that mutations in this same gene are responsible for
other phenotypes, including two forms of CMT periph-
eral neuropathy. DNM2-associated autosomal dominant
CMT2 neuropathy is characterized by progressive distal
muscle weakness and atrophy, predominantly in the
lower extremities, decreased or absent tendon reflexes,
steppage gait, foot drop, pes cavus [32, 33]. These clin-
ical features are in contrast with the presentation ob-
served in patients with DNM2-associated HSP described
here, although some overlap with CMT2 neuropathy ex-
ists, especially late in the disease. There has been active
discussion on the subject of similarity between some
forms of CMT neuropathy and HSP based on the identi-
fication of shared mechanisms involving central and per-
ipheral motor neurons (for review, see [5]). Interestingly,
mutations in KIF5A, a gene encoding the neuronal kine-
sin heavy chain implicated in anterograde axonal trans-
port, have been associated with “pure” HSP, although a
fraction of family members shows electrophysiological
evidence of sensory-motor peripheral axonal neuropathy
Table 5 Segregation analysis of four candidate variants in the
Siberian HSP family









II:6 Affected mut mut mut mut
III:2 Affected mut ref ref mut
III:3 Affected mut mut mut mut
III:7 Affected mut mut mut mut
IV:1 Affected nd nd nd mut
III:1 Unaffected mut ref ref ref
IV:2 Unaffected mut ref ref ref
IV:3 Unaffected ref nd ref ref
IV:4 Unaffected ref nd ref ref
mut mutated allele, ref reference allele, nd not done. The current age of the
unaffected family members (years): III:1 – 57; IV:2 – 39; IV:3 – 27; IV:4 – 30
Fig. 3 Identification of the disease-causing genetic variant. a Sequence chromatograph of a fragment of the DNM2 gene showing the position of
nucleotide substitution (arrow) responsible for the p.R719W mutation. b Protein alignment of the GTPase effector domain in various dynamins.
Mutated residue is colored red
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[34, 35]. Our findings give some weight to the view that
HSP and CMT caused by DNM2 mutations, although
clinically and anatomically separate syndromes, may
have some overlap due to shared pathological vulnerabil-
ities in their extended axonal processes.
Another DNM2-associated disease, autosomal-dominant
Centronuclear myopathy, is a slowly progressive congenital
myopathy characterized by delayed motor milestones, gen-
eralized muscle weakness, ptosis, and ophthalmoplegia
[14]. It includes a wide spectrum of phenotypes ranging
from severe neonatal to mild late-onset familial forms [36,
37]. CNM is characterized pathologically by myofiber atro-
phy, abnormal nuclear centralization and internalization,
and type 1 muscle fiber predominance [38]. Some patients
with CNM show clinical overlap of myopathy with mild
axonal involvement in peripheral nerves [39].
It remains to be determined why specific DNM2 muta-
tions result in involvement of skeletal muscle, peripheral
nerves, peripheral or corticospinal neurons. Existing hy-
potheses concentrate on different roles of dynamin 2 do-
mains involved in CMT or CNM. CMT mutations are
located within the pleckstrin homology [12] and proline-
rich domains [33], whereas the CNM mutations are
found within the PH domain. The significance of in-
volvement of specific dynamin domains is further under-
lined by the evidence we obtained in this study that the
HSP dynamin 2 mutation, p.R719W, is the only known
mutation in the bundle-signaling element of dynamin,
which is structurally and most likely functionally differ-
ent from the stalk and PH domains in which CMT and
CNM mutations are located. A mutation in this region
may cause a conformational change to the helical
element and affect dynamin assembly. Moreover, the
mutation results in fewer hydrogen bonds between the
bundle-signaling element and the stalk. A weaker con-
nection potentially uncouples the power stroke of dyna-
min from the rest of the molecule, a step that is
predicted to be essential for endocytosis [30].
Modeling in cell cultures of all known DNM2 muta-
tions causing either disease show their destructive effect
on clathrin-mediated endocytosis considered a major
mechanism for uptaking molecules into eukaryotic cells
regulated by dynamin [40, 41]. Clathrin-coated pits cap-
ture cargo molecules via adaptors, the pits invaginate
and pinch off to form clathrin-coated vesicles that carry
the cargo into the cell. Data presented here show that
the HSP-causing dynamin 2 p.R719W mutation induces
a marked decrease of clathrin-mediated endocytosis
similarly to other disease-causing dynamin 2 mutations,
suggesting that impairment of the membrane trafficking
process contributes to the pathogenesis of all DNM2-as-
sociated diseases. Prominent punctate staining in mutant
cells also suggests that the HSP DNM2 mutation affects
cellular morphology by mechanisms similar to previ-
ously characterized CMT and CNM mutations [12, 28].
The superfamily of dynamin GTPases comprises a
group of proteins that are involved in diverse cellular
functions and are often closely associated with biological
membranes; they function in vesicle scission, as well as
in fusion and fission of organelles [9]. The large GTPase
atlastin belongs to the dynamin superfamily and shares
the domain architecture with dynamin 2. Atlastin is in-
volved in ER fusion, vesicular trafficking, axon formation
and elongation. Mutations in atlastin isoform 1 (atlastin 1)
Fig. 4 Results of functional analysis of the c.2155C > T, p.R719W mutation. a HeLa cells transiently transfected with vectors containing the wild-
type (upper panel) and mutant (bottom panel) DNM2. The p.R719W mutant exhibits punctate pattern of DNM2 expression (arrowheads), whereas
cells transfected with wild type DNM2 show diffuse staining of the cytoplasm. Uptake of transferrin is reduced in cells expressing mutant DNM2
(arrows). Transferrin is labeled by Alexa-Flour 488 (green); nuclei are labeled with blue stain. b Quantification of transferrin uptake. The histogram
represents the mean +/− standard error of the corrected total transferrin fluorescence of WT (n = 30 cells) and p.R719W (n = 25 cells); P < 0.001
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have been identified in patients with early-onset HSP
(SPG3). Curiously, mutations in atlastin 1 have also been
associated with hereditary sensory neuropathy type 1D
(HSN1D; MIM# 613708), a condition characterized by
distal axonal sensory deficits leading to late distal skin ul-
ceration and amputation, with some patients showing
upper motor involvement [42]. The majority of atlastin 1
mutations are located in the GTPase domain, although
some have been identified in the stalk, the BSE, as well as
in the transmembrane domains [43] suggesting that mem-
brane association that is common to both representatives
of the dynamin family, dynamin 2 and atlastin 1, may be
critical in the pathophysiology of HSP.
Lack of DNM2 mutations in other Siberian HSP fam-
ilies suggests that more than a single gene is responsible
for this phenotype; HSP is an extremely heterogeneous
disorder with mutations in more than 60 genes associ-
ated with this syndrome.
Conclusions
Patients in the 4-generation Siberian family suffered
from hereditary spastic paraplegia and mild peripheral
axonopathy. Our molecular, structural and functional
analyses and segregation studies allowed to identify
DNM2 c.2155C > T, p.R719W mutation as a cause of
this disease. The mutation is located in a unique position
of the multidomain dynamin 2 protein and its patho-
genic effects may depend on structural relationships this
mutation disrupts. Awareness of the distinct, but partly
overlapping clinical phenotypes associated with muta-
tions in DNM2, will facilitate identification of these dis-
orders in additional families and direct future research
toward better understanding of the role dynamin 2 and
related networks have in health and disease.
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